Prognostic impact of the MDM2SNP309 Allele in Leukemia and Lymphoma

Sean M. Post, Vinod Pant, Hussein Abbas and Alfonso Quintás-Cardama _

PDF  |  How to cite

Oncotarget. 2010; 1:168-174. https://doi.org/10.18632/oncotarget.123

Metrics: PDF 2530 views  |   ?  


Received: July 7, 2010, Accepted: July 26, 2010, Published: July 27, 2010

A T-to-G germline single nucleotide polymorphism in the promoter region of MDM2 (SNP309) has been reported to markedly accelerate tumor formation in humans suggesting that it may represent a powerful cancer predisposing allele. Since its first description in 2004, a large number of retrospective analyses involving a wide variety of human malignancies have been reported, showing conflicting results regarding the impact of Mdm2SNP309 status on cancer risk and response to cancer therapy. Here, we appraise the available information on the effect of Mdm2SNP309 in lymphoma and leukemia and discuss the factors that likely account for the conflicting results observed in the studies reported to date.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 123